Table 5

Effect of PPAR-γ agonists on the histological grading of ankle synovium in arthritic rats.

Parameter

Normal controls

AIA controls

AIA + ROSI 10

AIA + PIO 30

Synoviocyte hyperplasia

0 ± 0

3.93 ± 0.12*

2.00 ± 0.42^#

0.80 ± 0.19^#

Focal aggregates of lymphocytes

0.08 ± 0.14

3.50 ± 0.24*

1.60 ± 0.23^#

1.20 ± 0.19^#

Fibrosis

0.37 ± 0.26

3.73 ± 0.20*

2.60 ± 0.31^#

1.00 ± 0.30^#

Proliferating blood vessels (original magnification × 40)

0.37 ± 0.26

1.50 ± 0.24*

0.80 ± 0.35

1.07 ± 0.12

Perivascular infiltrates of lymphocytes

0.62 ± 0.26

1.60 ± 0.31*

0.80 ± 0.35

1.10 ± 0.25

Diffuse infiltrates of lymphocytes

0 ± 0

3.13 ± 0.16*

2.10 ± 0.25^#

0.70 ± 0.22^#

PPAR, peroxisome proliferator-activated receptor; ROSI 10, rosiglitazone 10 mg/kg/day; PIO 30, pioglitazone 30 mg/kg/day; AIA, adjuvant-induced arthritis. Data are expressed as means ± SEM (n = 5 representative animals per group).

*, P < 0.05 compared with normal controls; ^#, P < 0.05 compared with AIA controls (Mann–Whitney U test).

Koufany et al. Arthritis Research & Therapy 2008 10:R6   doi:10.1186/ar2354